|
業務類別
|
-- |
|
業務概覽
|
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer. |
| 公司地址
| 55 Flemington Road, Level 4, North Melbourne, Melbourne, VIC, AUS, 3051 |
| 電話號碼
| +61 390933855 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.telixpharma.com |
| 員工數量
| 1184 |
| Dr. Christian Behrenbruch, M.B.A.,PhD |
Director, Managing Director and Group Chief Executive Officer |
美元 556.72K |
20/02/2026 |
| Ms. Genevieve Ryan |
Company Secretary |
-- |
20/02/2026 |
| Mr. Raphael Ortiz |
Chief Executive Officer, Telix International |
-- |
20/02/2026 |
| Mr. Kevin Richardson |
Chief Executive Officer, Telix Precision Medicine |
-- |
20/02/2026 |
| Dr. Mary Jessel |
Group Chief of Clinical Affairs |
-- |
20/02/2026 |
| Mr. Richard Valeix |
Chief Executive Officer, Telix Therapeutics |
美元 255.26K |
20/02/2026 |
| Ms. Lena Moran-Adams |
Group General Counsel |
-- |
20/02/2026 |
| Mr. David Cade, M.B.A.,M.D. |
Group Chief Medical Officer |
美元 368.90K |
20/02/2026 |
| Ms. Meredith Crowe |
Senior Vice President, People and Culture |
-- |
20/02/2026 |
| Mr. Darren Patti, Pharm.D. |
Group Chief Operating Officer |
美元 381.88K |
20/02/2026 |
| Mr. Darren Smith, M.B.A. |
Group Chief Financial Officer |
美元 488.99K |
20/02/2026 |
|
|
| Dr. Christian Behrenbruch, M.B.A.,PhD |
Director, Managing Director and Group Chief Executive Officer |
20/02/2026 |
| Ms. Marie McDonald |
Independent Director |
20/02/2026 |
| Ms. Jann Skinner, B.Com,F.C.A. |
Independent Director |
20/02/2026 |
| Dr. Mark Nelson, M.Phil,PhD |
Interim Chairman of the board |
20/02/2026 |
|
|
|
|
